Inhaled insulin: a novel route for insulin delivery

Insulin has been in use for the treatment of patients with diabetes mellitus for over 75 years. However, despite the known benefits of tight glycaemic control, multiple insulin injections have still not gained widespread clinical acceptance. Although there have been attempts to find effective non-invasive routes for insulin delivery, none of the novel non-invasive approaches have become part of established practice. In fact, until recently it was believed that as a result of limitations, non-invasive insulin was not a clinically realistic option. However, preliminary studies have indicated that inhaled insulin may emerge as an effective, well-tolerated, non-invasive alternative to subcutaneous regular insulin. The pharmacokinetics of inhaled insulin show a more physiological profile compared to conventional insulin; however, further studies to confirm long-term pulmonary safety and efficacy are needed.

[1]  Cefalu Wt Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. , 2001 .

[2]  F Vinicor,et al.  The continuing epidemics of obesity and diabetes in the United States. , 2001, JAMA.

[3]  W. Cefalu,et al.  Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.

[4]  W. Cefalu,et al.  Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study , 2001, The Lancet.

[5]  S. Schwartz,et al.  Pharmacological reproducibility of pre-meal inhaled insulin is comparable to injected insulin in patients with type 2 diabetes , 2000 .

[6]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[7]  Y Itakura,et al.  Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice. , 2000, Diabetes.

[8]  R. Newson,et al.  Injection related anxiety in insulin-treated diabetes. , 1999, Diabetes research and clinical practice.

[9]  Rury R. Holman,et al.  Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .

[10]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[11]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[12]  C. Saudek,et al.  Novel forms of insulin delivery. , 1997, Endocrinology and metabolism clinics of North America.

[13]  L. Heinemann,et al.  Time–action Profile of Inhaled Insulin , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[14]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[15]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[16]  P. Reichard,et al.  The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. , 1993, The New England journal of medicine.

[17]  M. Rewers,et al.  Global Estimates for Prevalence of Diabetes Mellitus and Impaired Glucose Tolerance in Adults , 1993, Diabetes Care.

[18]  J. Shipp,et al.  Insulin Across Respiratory Mucosae by Aerosol Delivery , 1971, Diabetes.

[19]  Ukpds,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes , 2002 .

[20]  W. Cefalu Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. , 2001, Annals of medicine.

[21]  A. Dobs,et al.  Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus. , 1998, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.